Navigation Links
Avicena to Advance Huntington's Disease Clinical Program into Phase III

Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases, announced today the selection of the optimal dose of HD-02, its novel drug candidate for the treatment of Huntington's Disease.

This dose was determined in an open-label dose escalation study, led by Dr. Steven Hersch and Dr. Diana Rosas of Massachusetts General Hospital (MGH), and will be further evaluated in a Phase III clinical trial.

The dose escalation study evaluated HD-02 in a range of doses from 10 to 40 grams per day and successfully determined the optimal dose that provided the maximum efficacy, safety and tolerability. The full scope of the data will be disseminated upon the results being peer reviewed.

Based on these findings, Avicena and its collaborators Dr. Hersch and the Huntington Study Group have developed a double-blind, placebo-controlled Phase III clinical trial anticipated to commence in early 2008. The Phase III trial will be one of the single largest trials for Huntington's patients, with external funding to be announced.

Upon commencement of this clinical trial, Avicena will have advanced three different indications into phase III trials that include some of the largest trial to date in both Parkinson's and Huntington's.

"We are very encouraged by the results of our HD-02 trial and we believe that in conjunction with our collaborators at MGH, we have identified the optimal dose as we move forward to validate HD-02 as a potential treatment for Huntington's disease, for which there is no current approved drug by the FDA.

We are committed to developing therapeutics that we hope can slow the progression of neurodegenerative diseases," stated Belinda Tsao-Nivaggioli, CEO of Avicena.

"We are excited by the results of our studies with HD-02 to date. This Phase III study will evaluat e whether HD-02 can slow the progression of Huntington's disease and translate into real-world clinical benefits for patients," stated lead investigator Dr. Steven Hersch.

ABOUT HD-02 HD-02 is a novel drug candidate for the treatment of Huntington's disease (HD) with orphan drug designation in the U.S. Avicena has recently completed a Phase II clinical study of HD-02 led by Dr. Steven Hersch of Massachusetts General Hospital.

Results from this study, which were published in the January 24, 2006 issue of Neurology, showed that HD-02 reduced the Huntington's disease marker, which some researchers have linked to brain injury. Further studies by Dr. Hersch and Dr. Rosas have optimized the dosing of HD-02 and provided further evidence supporting its potential to slow HD.

Earlier preclinical studies performed by Dr. Flint Beal of Cornell Medical Center and Dr. Robert Ferante of Boston University, HD-02 have shown significant neuroprotective effects such as improved motor movement and increased survival rate.

Avicena intends to collaborate with Dr. Hersch and the Huntington Study Group to initiate a Phase III trial in early 2008 following completion of a chronic toxicology study that is currently underway.




'"/>




Related medicine news :

1. Advances in Treatment of Cataracts
2. Advanced STD programs required
3. Hope For Patients With Advanced Breast Cancer
4. Advances In Stem Cells Research
5. Breast Cancer Advance
6. Canadian Lung Cancer Study Lauded As Major Advance in Cancer Fight
7. Speedier Access To Advances In Breast Cancer Sought For Patients
8. HIV Vaccine Field Trials In Advanced Stage
9. Advance Funeral For AIDS-infected South African
10. New Screening Techniques to Lead Advances In Pain Therapy
11. Twin Treatment Could Be Used Increase Survival Rates In Advanced Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/2/2016)... ... 02, 2016 , ... ‘Tis the season for giving! Today, 20 creative teams ... Family Partnership and the Drug Enforcement Administration as part of the National Red Ribbon ... winning schools who decorated their campuses with this year’s Red Ribbon Week theme: “YOLO. ...
(Date:11/30/2016)... ... November 30, 2016 , ... Northridge ... in-house dental plan for all patients. Understanding that budget can play a part ... a number of perks, including discounts on many valuable dental treatments. Options for ...
(Date:11/30/2016)... Wisconsin (PRWEB) , ... November 30, 2016 , ... ... in the 2016 Deloitte Wisconsin 75, an annual ranking and recognition of the ... year on the list, having ranked from 2008-2016. In addition, Standard Process was ...
(Date:11/30/2016)... (PRWEB) , ... November 30, 2016 , ... ... and mental health treatment has announced the opening of a new residential mental ... for girls with mental health issues such as severe anxiety, depression, bi-polar disorder, ...
(Date:11/30/2016)... ... November 30, 2016 , ... The ... stylish design wanted by today’s consumers at an affordable price, is now available ... the new watch is “a game changer” when it comes to the smartwatch. ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , December 2, 2016 ... "In Vitro Diagnostics/IVD Market by Product (Instruments, Reagents, ... Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) - ... market is valued at USD 60.22 Billion in ... a CAGR of 5.5% during the forecast period ...
(Date:12/2/2016)... 2016  The Addiction Treatment Advisory Group (ATAG), ... Care Pharmacy (AMCP), has released detailed findings on ... opioid addiction crisis, including through improved access to ... ATAG,s newly released paper, "The Role of Managed ... many issues around gaps and barriers to addiction ...
(Date:12/2/2016)... 2, 2016 Boston Scientific Corporation (NYSE: ... acquire certain manufacturing assets and capabilities of the Neovasc, ... biological tissue business, as well as a 15% equity ... in cash. The Neovasc advanced biological tissue business makes ... Scientific Lotus™ Valve System. * Upon completion of ...
Breaking Medicine Technology: